Updated on 15 March 2013
The color discrimination is excellently exemplified in controlled tissue culture experiments showing that while cancer cells are stained red by the CellDetect technology, treatment of the same cells with chemicals known to affect the cancer, phenotype, causes these cells to stain green. In human tissue sections, CellDetect readily differentiates normal cells and tissues from neoplastic cells and tissues by both color and morphology.
According the agreement, Biomics Biotechnologies will pay Zetiq Technologies royalties at the rate of 16 percent on direct sales of the product generated by Biomics or 25 percent royalties of the income of Biomics from sales generated by any sub-distributor.
It also has a subsidiary Genecon Biotech. "Biomics' main business is RNAi-based drug development. In order not to distract from the focus of the parental company, we started Genecon to apply RNAi in the cosmetic sector for anti-hyperpigmentation (anti-skin blotch) to show the power of RNAi in application," says Dr York Zhu.
The company has several products, such as chemical synthesis of RNA, large-scale RNA synthesis of up to 100 gram and RNA modification and labeling. It also specializes in high throughput siRNA target screening (library base), RNA vector construction, dual luciferase reporting system, protein expression and RNAi-related services.
It owns integrated technology platforms, including entire siRNA targets (EsT) library, multiplex siRNA, small ligand RNA (sliRNA) and RNA modification. Together with Genecon Biotech, a subsidiary of the company, it has developed local (transdermal) and systematic delivery systems. Now, the company is focusing on second-generation delivery systems that can enter hypodermis (epidermis) and follicle (local), and targeted delivery.